Marginal Zone B-cell Lymphoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2015-10-12
Clinical Trial Update: Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas [Phase 2]
This clinical trial update notes that the Phase 2 study of the anti-CD20 antibody ofatumumab in older patients with untreated indolent B-cel…